deListed Australia
 
SEARCH LISTED OR DELISTED COMPANY
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY
SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

MELODIOL GLOBAL HEALTH LIMITED (ASX.ME1)

ASX Announcements (courtesy of ASX)

20232024

ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)
2023 2024   ALL
Former (or subsequent) names
CompanyFROMTO
MELODIOL GLOBAL HEALTH LIMITED13/06/2023
CRESO PHARMA LIMITED13/06/2023
Shareholder links
Our website ranking of ME1: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details
ISIN: AU0000282840
Address: Suite 5 CPC 145 Stirling Highway Nedlands, Western Australia, 6009
Tel:  +61 (8) 9389 3180 Fax: +61 8 9481 4950

Date first listed: 20/10/2016

Sector: Pharmaceuticals, Biotechnology & Life Sciences
Activities: Developing, registering and commercialising pharmaceutical-grade cannabis and hemp-based products for use across a broad spectrum of consumer, industry and research applications

delisted by ASX under Listing Rule 17.12

28/10/2024

we understand ASX determined that ME1 was unable or unwilling to comply with, or has broken, Listing Rules 2.6 and 16.4. (rules that mandate fees are to be paid for the quotation of additional securities)

28/10/2024

The company releases a notification of cessation of securities.

27/09/2024

The quoted options exercisable at $15.00 each will expire at 5.00pm WST on 2 November 2024. The listed options are out of the money.

27/09/2024

The company lodges its notice of cessation of securities.

04/09/2024

The securities of Melodiol Global Health Limited will be suspended from Official Quotation at the close of trading on Wednesday, 28 August 2024 under Listing Rule 17.3.1. ASX has determined that ME1 has been unable or unwilling to comply with, or has broken, Listing Rules 2.6 and 16.4. The suspension will continue until ASX is satisfied that ME1 is in compliance with the Listing Rules, including Listing Rules 2.6 and 16.4, and that it is otherwise appropriate for ME1's securities to be reinstated to quotation.

28/08/2024

name changed from Creso Pharma Limited

13/06/2023
View ASX Announcements (courtesy of ASX)

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments

What will happen to my money invested on this useless company?

01/11/2024 11:22:28

How can I get rid of this useless stock 

29/10/2024 15:34:24
Company Updates
Post your comments here
Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    07/07/2021Adam Blumenthal32,833,333$0.138$4,538,059

    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    NAMETITLEDATE OF APPT
    William LayManaging Director, CEO17/01/2022
    Tim TianCFO01/05/2024
    Ben QuirinNon Exec Director10/10/2022
    Peter HatfullNon Exec Director30/11/2022
    Boaz WachtelNon Exec Director22/11/2015
    Bruce LintonNon Exec Director17/01/2022
    Micheline MacKayExecutive Director17/01/2022
    Winton WilleseeCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)
    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Chris GrundyCFO04/12/201701/05/2024
    Jodi ScottExecutive Director10/10/202230/04/2024
    James EllingfordExecutive Director22/11/201501/12/2022
    Adam BlumenthalNon Exec Chairman22/11/201510/10/2022
    Miri WernliExecutive Director20/10/201617/03/2021
    David RussellCOO04/04/201704/12/2017
    Simon BuckinghamNon Exec Director20/10/201601/06/2017

    Date of first appointment, title may have changed.